BYSI

BeyondSpring Inc.

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Fabbio PatrickDirector
$36k22.2k shares
Grant / ExerciseApr 1, 2026
$36.4K22.2k shares
$1.64
--
Kirkby MatthewDirector
$39k23.9k shares
Grant / ExerciseApr 1, 2026
$39.2K23.9k shares
$1.64
--
Majeti JiangwenDirector
$36k21.7k shares
Grant / ExerciseApr 1, 2026
$35.6K21.7k shares
$1.64
--
Delaney BrendanDirector
$34k20.4k shares
Grant / ExerciseApr 1, 2026
$33.5K20.4k shares
$1.64
--
Lu Yingjuan JuneChief Scientific Officer
$29k17.8k shares
Grant / ExerciseApr 1, 2026
$29.3K17.8k shares
$1.64
--
Xu SihaiDirector
$31k18.7k shares
Grant / ExerciseApr 1, 2026
$30.6K18.7k shares
$1.64
--

News

globenewswire.comBeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Valueglobenewswire.comJun 4globenewswire.comBeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026globenewswire.comJun 2globenewswire.comBeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026globenewswire.comJun 2globenewswire.comBeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meetingglobenewswire.comMay 18globenewswire.comBeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 13